Search Results for “Pfizer” – Page 41 – media

Investors place bet on Chinese drugmakers

Chinese biotech groups are on target to raise about $10bn this year from venture capital funding, initial public offerings and licensing deals with overseas pharma companies, in what is partly a bet that Chinese-developed drugs can compete globally.
- Source: ft
- 872
- November 24, 2017
China drug innovation pharmaceutical R&D
Shooting for a new standard on osteoarthritis, Merck KGaA outlines promising data for a potential game-changer

Merck KGaA’s pharma group is taking one more step in a long journey toward rehabbing its rep in the R&D field this weekend. Company execs turned up at the ACR scientific conference in San Diego to roll out a promising look at some key Phase II osteoarthritis data — which comes with a critical caveat.
- Source: Endpts
- 645
- November 13, 2017
Merck osteoarthritis R&D sprifermin
China’s Import and Export Report of Antineoplastic Drugs

Antineoplastic or anticancer drugs, affect the process of cell division i.e. are antiproliferative. They damage the DNA and initiate apoptosis, preventing the development and spread of neoplastic cells. Commonly used antineoplastic drugs can be divided into the following six categories: alkylating agents, anti-metabolites, anticancerous, antibiaties, aminoglutethimide and others. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, shares China’s Import and Export Report of Antineoplastic Drugs with you. General situation of global market of antineoplastic drugs According to the IMS’s latest report, “Global Oncology Trends 2017” showed that in 2016 the global market sales of antineoplastic drugs were 89.6 billion USD and 85 billion USD in 2015. Over the past five years, the global market of antineoplastic drugs has grown at a compound annual growth rate (CAGR) of 8.7% and is expected to exceed 147 billion USD by 2021. As indicated on the chart, the United States, the European Union and Japan are still the driving ...
- Source: Ddu
- 1,499
- November 3, 2017
anticancer Antineoplastic Market Reports neoplastic cells
CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck & Co.
- Source: Pmlive
- 924
- October 30, 2017
Company Insight HIV Shingrix Tivicay Triumeq vaccine
China’s Cardiovascular Drugs Import and Export Report

Cardiovascular drugs are medicines used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and strokes, whose therapeutic effects aim to improve cardiac functions, regulate blood flow of heart and change the circulatory system of blood distribution among other things.
- Source: Ddu
- 1,548
- October 19, 2017
cardiovascular Market Reports
NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 551
- October 16, 2017
Market Views NIH PACT
China’s Antimicrobial Drug Import and Export Market Report

"Antimicrobial" is a general term which refers to a group of drugs that includes antibiotics, antifungals, antiprotozoals and antivirals, which are destructive or have inhibiting effect to bacteria, fungi and chlamydia and is one of the most widely used drugs in clinical trials.
- Source: Ddu
- 1,410
- October 13, 2017
Antimicrobial export import Market Reports
AstraZeneca’s Tagrisso Gets Breakthrough Therapy Designation

AstraZeneca announced that the FDA has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 579
- October 10, 2017
Company Insight EGFR FDA New Approvals NSCLC
Big Pharma Gets Boost as China Speeds Up New Drug Approvals

For decades, Chinese patients have struggled to gain access to cutting-edge medicines thanks to bureaucratic delays that have hamstrung drug development. Now a sweeping government overhaul of drug approvals is poised to change that.
- Source: bloomberg
- 512
- October 10, 2017
Chinese drug approval Market Views
ViiV’s long-acting two-drug HIV regimen hits targets

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who had already achieved viral suppression with a daily three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs). Following 96 weeks of maintenance treatment, viral suppression rates for the two-drug regimen dosed every eight weeks (94 percent) or every four weeks (87 percent) were comparable to the rate observed in patients continuing with a three-drug oral regimen (84 percent). In the study, data from which were published in The Lancet and presented at the annual conference ...
- Source: Medicaldevice-network
- 512
- July 27, 2017
Clinical Trials formulation HIV Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.